ResMed share price marching higher amid 'significant victory' for ASX 200 healthcare stock

ASX 200 healthcare share ResMed has more than 9,500 issued or pending patents and designs.

The ResMed Inc (ASX: RMD) share price is marching higher today.

Shares in the S&P/ASX 200 Index (ASX: XJO) healthcare stock closed yesterday trading for $24.75. In late morning trade on Tuesday, shares are swapping hands for $24.98 apiece, up 0.9%.

For some context, the ASX 200 is up 0.3% at this same time.

This comes on the heels of a legal victory for the company, which develops and sells digital health technologies and cloud-connected medical devices.

Here's what's happening.

Cropped shot of a young female scientist working on her computer in the laboratory.

Image source: Getty Images

Patent victory for ASX 200 healthcare stock

The ResMed share price is in the green today after the company reported it had won "a significant victory" against New York University (NYU).

ResMed said the United States Patent Trial and Appeals Board has ruled against patent infringement claims lodged by NYU in June 2021.

In its complaint, NYU alleged that the AutoSetTM and AutoRampTM features of ResMed's AirSenseTM 10 AutoSet flow generators, infringed one or more claims of seven NYU patents.

ResMed defended its tech and asserted NYU's claims were invalid. The US Patent Trial judges agreed and have now found that all the challenged claims across the seven patents were invalid.

Commenting on the legal win that looks to be giving the ResMed share price some tailwinds today, Michael Rider, ResMed's global general counsel and secretary said, "We will continue to vigorously defend our innovations."

Rider added:

The fact that our intellectual property contributed to this victory is a testament to our investment in research and development, the hard work of our inventors, and the patent protection we pursue to protect our innovation.

ResMed CEO Mick Farrell said, "Our sustained investment in research and development for over 30 years has culminated in more than 9,500 issued or pending patents and designs."

Farrell applauded the ruling and said ResMed will defend its innovations, "ensuring patients continue to receive our therapy solutions, empowering them to live healthier, higher-quality lives."

ResMed share price snapshot

The ResMed share price is down 18% in 2023.

The past month has seen a positive turn for the ASX 200 healthcare stock, with shares up 11%.

Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended ResMed. The Motley Fool Australia has positions in and has recommended ResMed. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Doctor sees virtual images of the patient's x-rays on a blue background.
Healthcare Shares

Could this ASX biotech really jump more than 80% in value?

This company's new technology has one broker impressed.

Read more »

Teamwork, planning and meeting with doctors and laptop for medical, review and healthcare. Medicine, technology and internet with group of people for collaboration, diversity and support in hospital
Healthcare Shares

CSL vs Pro Medicus: Which ASX healthcare share is better?

Both CSL and Pro Medicus have faced recent challenges but have enviable long-term track records. Here's which one I'd buy…

Read more »

Scientists working in the laboratory and examining results.
Healthcare Shares

This ASX biotech could rise almost 50%, Morgans says

Turning science into contracts could unlock value for this company.

Read more »

Doctor with stethoscope using a tablet in a hospital.
Healthcare Shares

Telix Pharmaceuticals wins FDA Fast Track for BiPASS prostate cancer imaging

Telix Pharmaceuticals shares are in the spotlight after the FDA granted Fast Track for its BiPASS pre-biopsy prostate cancer imaging…

Read more »

Three scientists looking at a laptop in a lab.
Healthcare Shares

What would it take for CSL shares to return to $250?

The shares have already recovered strongly, so I wanted to see whether $250 is realistic.

Read more »

Doctor with stethoscope typing on her computer.
Healthcare Shares

Is the ResMed share price a cheap buy?

I look at what the next few years of earnings growth could mean for today’s valuation.

Read more »

Medical workers examine an x-ray or scan in a hospital laboratory.
Healthcare Shares

Expert names 'undervalued' ASX 200 healthcare stock to buy today

A top fundie expects more outperformance from this resurgent ASX healthcare share.

Read more »

A gavel is placed on a stand on a desk with a legal representative wearing a suit in the background.
Healthcare Shares

Cochlear shares fall as investors face another setback

Cochlear shares are back in the red.

Read more »